<DOC>
	<DOCNO>NCT01462786</DOCNO>
	<brief_summary>The objective trial evaluate safety tolerability ATX-101 injection compare pharmacokinetic profile ATX-101 administer subcutaneous fat submental area abdomen .</brief_summary>
	<brief_title>To Evaluate Safety , Tolerability Compare Pharmacokinetic Profile ATX-101</brief_title>
	<detailed_description />
	<criteria>1 . Presence submental fat grade investigator 3 4 use SMF Rating Scale ( Appendix C ) guideline . 2 . Sufficient submental abdominal fat protocolspecified number injection safely administer . 3 . Males nonpregnant , nonlactating female age 18 65 year , inclusive , date dosing ATX101 . Females must negative serum human chorionic gonadotropin ( HCG ) test result sample obtain screening period admission research facility first confinement period , dose study material . Females postmenopausal status must menses least one year young 55 year age must serum FSH level â‰¥ 35 mIU/mL . Females childbearing potential must agree practice adequate contraception , judgment investigator , course trial . 4 . A normal result coagulation test ( PT , PTT ) obtain within 28 day subject 's first dosing session . 5 . Serum hemoglobin test result 12.0 g/dL great negative hepatitis B , hepatitis C , HIV test result within 28 day dose study material . 6 . Ability comply understand visit schedule protocolspecified test procedure . 7 . Medically able undergo administration study material determine clinical laboratory evaluation obtain within 28 day dose study material investigator identifies clinically significant abnormality . 8 . Signed informed consent obtain studyspecific procedure conduct . 1 . History intervention treat submental abdominal fat ( e.g. , liposuction , surgery , lipolytic agent ) . 2 . History trauma associate chin , neck , abdominal area , judgment investigator may affect evaluation safety efficacy treatment . 3 . Loose skin neck chin area reduction submental fat may , judgment investigator , result cosmetically unacceptable outcome . 4 . Prominent platysmal band rest interfere evaluation submental fat . 5 . Evidence cause enlargement submental abdominal area localize subcutaneous fat . 6 . Obesity define body mass index ( BMI ) &gt; 34 screen visit . Refer Appendix B . 7 . Any blood donation significant blood loss within 56 day dose study material plasma donation within 7 day dose study material . 8 . Any medical condition ( e.g. , respiratory , cardiovascular , hepatic , neurological disease , uncontrolled hypertension , thyroid dysfunction ) , would interfere assessment safety trial would compromise ability subject undergo study procedure give inform consent . 9 . Treatment fish oil , aspirin , nonsteroidal antiinflammatory agent ( NSAIDS ) , except acetaminophen , within seven day dose , anticipated need agent anticoagulative effect ( e.g. , warfarin , heparin ) course trial . 10 . Treatment oral anticoagulant ( e.g. , warfarin ) within 30 day dose study material . 11 . Expected require treatment systemic medication study period ( exclude protocolspecified treatment ) 12 . Treatment radio frequency , laser procedure , chemical peel , dermal filler neck chin area within 12 month first treatment session , botulinum toxin injection neck chin area within 6 month first treatment session . 13 . History sensitivity component study material topical anesthetic ( e.g. , lidocaine , benzocaine , novocaine ) . 14 . History drug alcohol abuse , judgment investigator , within two year dose study material . 15 . Presence positive urine drug alcohol screen test result obtain sample obtain screening period and/or admission research facility confinement period , dose study material . 16 . Previous enrollment trial ATX101 . 17 . Treatment investigational agent within 30 day dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>